Figure 1. Total incidence of IE from 2011 to 2016.
| Journal of Clinical Medicine Research, ISSN 1918-3003 print, 1918-3011 online, Open Access |
| Article copyright, the authors; Journal compilation copyright, J Clin Med Res and Elmer Press Inc |
| Journal website http://www.jocmr.org |
Original Article
Volume 9, Number 9, September 2017, pages 754-758
Epidemiology of Infective Endocarditis in Rural Upstate New York, 2011 - 2016
Figures
Tables
| Year of admission | Number of cases diagnosed with IE | Number of cases with reported IV drug use | Percentage (%) of cases using IV drugs |
|---|---|---|---|
| 2011 | 6 | 1 | 16.7 |
| 2012 | 5 | 1 | 20 |
| 2013 | 9 | 1 | 11.1 |
| 2014 | 8 | 0 | 0 |
| 2015 | 14 | 6 | 42.9 |
| 2016 | 12 | 4 | 33.3 |
| Variables | IE, 2011 - 2016, n = 54 |
|---|---|
| Demographics | |
| Age, median years (range) | 61.5 (21 - 93) |
| Female gender | 19 (35%) |
| Race (Caucasian) | 54 (100%) |
| Diagnosis | |
| Definite IE | 45 (85%) |
| Possible IE | 9 (14%) |
| Comorbidities | |
| Diabetes mellitus | 21 (38.8%) |
| HIV | 1 (1.85%) |
| Neoplasm | 6 (11.1%) |
| Other immunosuppressed states | 2 (3.7%) |
| Valvular heart disease | 15 (28.8%) |
| Heart failure | 11 (20.4%) |
| Bicuspid aortic valve | 1 (1.85%) |
| Atrial fibrillation | 13 (24.07%) |
| Distant infections | 12 (22.2%) |
| Pulmonary disease | 11 (20.37%) |
| Renal insufficiency | 13 (24.1%) |
| Dialysis dependent | 7 (12.9%) |
| Predisposing factor | |
| Rheumatic heart disease | 1 (1.85%) |
| Mitral valve prolapse | 0 |
| IV drug use | 13 (24.1%) |
| Previous cardiac surgery | 16 (29.6%) |
| Congenital heart disease | 1 (2.38 %) |
| Previous IE | 12 (22.2%) |
| Implantable intra-cardiac device | 8 (14.8%) |
| Central venous line | 6 (11.1%) |
| Affected valve | |
| Native valve | 39 (72.2%) |
| Prosthetic valve | 7 (12.9%) |
| Lead infection | 8 (14.8%) |
| Aortic | 12 (22.2%) |
| Mitral | 26 (48%) |
| Tricuspid | 7 (12.9%) |
| Pulmonary | 3 (5.5%) |
| Site of acquisition | |
| Community acquired | 43 (79.6%) |
| Nosocomial | 2 (3.7%) |
| Healthcare associated | 9 (16.7%) |
| Causative organism | |
| S. aureus | 21 (38.3%) |
| MSSA | 14 (66.6%) |
| MRSA | 7 (33.3%) |
| Coagulase negative Staph | 6 (11%) |
| Streptococcus species | 9 (16.6%) |
| Enterococcus | 9(16.6%) |
| Culture negative | 6 (11%) |
| Others | 3 (5.5%) |
| Outcomes | |
| Median length of stay | 11 |
| In-hospital death | 3 (5.5%) |
| 6-month mortality | 5 (9.2%) |
| Valve surgery indicated (within 6 weeks) | 15 (27.7%) |
| Valve surgery indicated (6 week to 1 year) | 3 (5.5%) |
| Valve surgery performed (within 6 weeks) | 8 (14.8%) |
| Valve surgery performed (6 week to 1 year) | 4 (7.4%) |